lopinavir has been researched along with Atrophy in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Capeau, J; Danner, SA; Domingo, P; Feeney, ER; Mallon, PW; Reiss, P; van Agtmael, MA; van Vonderen, MG; Villarroya, F; Wit, F | 1 |
| Arribas, JR; Arrizabalaga, J; Bernardino, JI; Domingo, P; Martinez, E; Muñoz, J; Ocampo, A; Portilla, J; Pulido, F; Torres, R | 1 |
2 trial(s) available for lopinavir and Atrophy
| Article | Year |
|---|---|
Zidovudine/lamivudine but not nevirapine in combination with lopinavir/ritonavir decreases subcutaneous adipose tissue mitochondrial DNA.
Topics: Absorptiometry, Photon; Acquired Immunodeficiency Syndrome; Adolescent; Adult; Aged; Anti-HIV Agents; Atrophy; CD4 Lymphocyte Count; DNA, Mitochondrial; Drug Combinations; Drug Therapy, Combination; HIV Seropositivity; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Nevirapine; Prospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Subcutaneous Fat; Treatment Outcome; Young Adult; Zidovudine | 2012 |
Switching to lopinavir/ritonavir with or without abacavir/lamivudine in lipoatrophic patients treated with zidovudine/abacavir/lamivudine.
Topics: Absorptiometry, Photon; Adipose Tissue; Adult; Antiretroviral Therapy, Highly Active; Atrophy; Body Composition; Chemistry, Pharmaceutical; Dideoxynucleosides; Female; HIV Infections; HIV Protease Inhibitors; Humans; Intention to Treat Analysis; Lamivudine; Lipids; Lipodystrophy; Lopinavir; Male; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Failure | 2013 |